Viking Therapeutics, Inc. VKTX

VKTX Company Overview

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company operates within the biotechnology and pharmaceuticals industry and does not currently have any commercialized products, generating no recurring product revenue. Its business model is centered on discovering, developing, and advancing small-molecule and peptide-based drug candidates through clinical trials, with value creation driven by clinical milestones and capital markets activity.

Viking’s primary strategic positioning is its focus on high-prevalence metabolic diseases with significant unmet medical need, particularly obesity and related cardiometabolic conditions. The company’s pipeline has evolved over time, narrowing its focus as clinical data has emerged. Founded in 2012, Viking Therapeutics has transitioned from a broader endocrine pipeline to a more concentrated emphasis on obesity and metabolic dysfunction, reflecting shifts in both clinical outcomes and market opportunity.